Methotrexate (MTX), an anti-cancer chemotherapy and anti-rheumatoid agent, exerts its antiviral activity by inhibiting the dihydrofolate reductase (DHFR) in different cell lines, restricting the synthesis of adenosine triphosphate and disrupting ZIKV replication [109]. This evidence concerns the gene DHFR and cancer.